Effect of KSG-504, a new CCK-A-receptor antagonist, on experimental acute pancreatitis in rats and mice

Folia Pharmacologica Japonica

Volumn 107, Issue 4, 1996, Pages 194-195

  Kobayashi, Mamoru ^a   Shinagawa, Kazuhiko ^a   Sugiura, Masaru ^a   Nagasawa, Tatsuya ^a   Akahane, Masuo ^a   Ajisawa, Yukiyoshi ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; ARGINIUM 4 [N (3 METHOXYPROPYL) N PENTYLCARBAMOYL] 5 (2 NAPHTHYLSULFONYL)PENTANOATE; CERULETIDE; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLINE; ETHIONINE; TAUROCHOLIC ACID; TRIACYLGLYCEROL LIPASE;

ACUTE PANCREATITIS; AMYLASE BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CONTROLLED STUDY; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORGAN WEIGHT; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VITAMIN DEFICIENCY;

ACUTE DISEASE; AMYLASES; ANIMALS; CAERULEIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; LIPASE; MALE; MICE; MICE, INBRED ICR; NAPHTHALENES; PANCREAS; PANCREATITIS; PENTANOIC ACIDS; RATS; RATS, WISTAR; RECEPTOR, CHOLECYSTOKININ A; RECEPTORS, CHOLECYSTOKININ;

EID: 0029870897     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.107.183     Document Type: Article

References (30)

1. Rinderknecht H, Stace NH and Renner IG: Effects of chronic alcohol abuse on exocrine pancreatic secretion in man. Dig Dis Sci 30, 65-71 (1985)
2. Yamazaki Y, Akahane M, Kobayashi M, Kitazawa M, Kurashina Y and Iizuka K: Pharmacological profile of KSG-504, a new cholecystokinin-A-receptor antagonist. Jpn J Pharmacol 63, 219-225 (1993)
3. Tani S, Otsuki M, Itoh H, Fujii M, Nakamura T, Oka T and Baba S: Histological and biochemical alterations in experimental acute pancreatitis induced by supramaximal caerulein stimulation. Int J Pancreatol 2, 337-348 (1987)
4. Makovec F, Bani M, Cereda R, Chiste R, Revel L, Rovati LC, Setnikar I and Rovati LA: Protective effect of CR-1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice. Peptides 7, 1159-1164 (1986)
5. Niederau C, Liddle RA, Ferrell LD and Grendell H: Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhage in mice. J Clin Invest 78, 1056-1063 (1986)
6. Satomura S, Okajima S, Hamanaka T, Shintani A, Miyashita Y and Sakata Y: Kinetics of human pancreatic and salivary α -amylase with carboxymethyl-amylose as substrates. Clin Chim Acta 138, 21-29 (1984)
7. 9) Med Technol 12, 31-39 (1984)
8. Niederau C, Ferrell LD and Grendell JH: Caerulein-induced acute necrotizing pancreatitis in mice. Gastroenterology 88, 1192-1204 (1985)
9. Adler G, Hupp T and Kern HF: Course and spontaneous regression of acute pancreatitis in the rat. Virchows Arch A Pathol Anat Histopathol 382, 31-47 (1979)
10. Willemer S, Elsasser HP and Adler G: Hormone-induced pancreatitis. Eur Surg Res 24, 24-39 (1992)
11. Owyang C, Dexter SL and Donald T: Feedback regulation of pancreatic enzyme secretion. Suppression of cholecystokinin release by trypsin. J Clin Invest 77, 2024-2047 (1986)
12. Aho HJ, Koskensalo SML and Nevalainen TJ: Experimental pancreatitis in the rat. Scand J Gastroenterol 15, 411-416 (1980)
13. Tani S, Okabayashi Y, Nakamura T, Fujii M, Itoh H and Otsuki M: Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models. Pancreas 5, 284-290 (1990)
14. Watanabe N, Ogami Y, Nakano S, Kihara Y and Otsuki M: Effect of CCK receptor antagonists on bile secretion. Gastroenterology 102, A338 (1992)
15. Miyasaka K, Funakoshi A, Jimi A, Nakamura R, Matsumoto M and Kitani K: Changes in plasma and duodenal cholecystokinin concentrations after pancreatic duct occlusion in rats. Dig Dis Sci 37, 369-377 (1992)
16. Setnikar I, Bani M, Cereda R, Chiste R, Macovec F, Pacini MA and Revel L: Loxiglumide protects against experimental pancreatitis. Arzneimittelforschung 37, 1172-1174 (1987)
17. 3H]-(±)-L364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. Mol Pharmacol 30, 212-217 (1986)
18. Silverman M, Irardi C, Bank S, Kranz V and Lendvai S: Effects of the cholecystokinin receptor antagonist L-364,718 on experimental pancreatitis in mice. Gastroenterology 96, 186-192 (1989)
19. Ohshio G, Saluja A, Leli U, Sengupta A and Steer ML: Failure of a potent cholecystokinin antagonist to protect against diet-induced pancreatitis in mice. Pancreas 4, 739-746 (1989)
20. Grandell JH: Experimental pancreatitis. In Cholecystokinin Antagonists in Gastroenterology, Edited by Adler G and Beglinger C, pp 197-202, Springer-Verlag, Berlin (1991)
21. Pullen RGL and Hodgson OJ: Penetration of diazepam and non-peptide CCK antagonist, L-364,718 into rat brain. J Pharm Pharmacol 39, 863-864 (1987)
22. Daniel AC and Roger DR: Diurnal variation in the effects of type A CCK receptor antagonist devazepide on meal patterns in rats. Ann NY Acad Sci 713, 429-430 (1994)
23. Gilliland L and Steer ML: Effects of ethionine on digestive enzyme synthesis and discharge by mouse pancreas. Am J Physiol 239, G418-G426 (1980)
24. Barrowman JA and Mayston PD: The trophic influence of cholecystokinin on the rat pancreas. J Physiol 238, 73P-75P (1973)
25. Haarstad H and Petersen H: The effects of graded doses of a cholecystokinin-like peptide with and without secretin on pancreatic growth and synthesis of RNA and polyamines in rats. Scand J Gastroenterol 24, 907-915 (1989)